[1]林慧,陈佳菁,陈燕红,等.高危型HPV检测和TCT在宫颈癌前病变筛查中的应用价值股骨头中心与邻近骨性标志关系的研究[J].福建医药杂志,2022,44(05):21-24.
　LIN Hui,CHEN Jiajing,CHEN Yanhong,et al.Application value of high-risk HPV detection and TCT in screening cervical precancerous lesions[J].FUJIAN MEDICAL JOURNAL,2022,44(05):21-24.
点击复制

高危型HPV检测和TCT在宫颈癌前病变筛查中的应用价值股骨头中心与邻近骨性标志关系的研究()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
44
期数:
2022年05期
页码:
21-24
栏目:
临床研究
出版日期:
2022-10-15

文章信息/Info

Title:
Application value of high-risk HPV detection and TCT in screening cervical precancerous lesions
文章编号:
1002-2600（2022）05-0021-04
作者:
林慧; 陈佳菁; 陈燕红; 邱建龙
中国人民解放军联勤保障部队第910医院病理科（泉州 362000）
Author(s):
LIN Hui; CHEN Jiajing; CHEN Yanhong; QIU Jianlong
Department of Pathology, the 910th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Quanzhou, Fujian 362000, China
关键词:
人乳头瘤病毒; 液基细胞学; 宫颈癌前病变; 应用价值
Keywords:
human papillomavirus;  liquid based cytology;  cervical precancerous lesions;  application value
分类号:
R737.33
文献标志码:
B
摘要:
目的 探讨高危型人乳头瘤病毒（HR-HPV）检测和液基薄层细胞学检查（TCT）在宫颈癌前病变筛查中的应用价值。 方法 回顾性分析2018年1月至2020年12月我院的宫颈癌筛查资料。选取15 162名进行TCT和HR-HPV联合筛查的人员作为研究对象，包括体检11 831例，妇科患者3 331例，了解福建泉州地区不同人群HR-HPV的感染状况。另外选取1 220例TCT、1 428例HR-HPV检测以及843例联合筛查数据，以宫颈活检结果为标准，比较不同筛查方法对宫颈鳞癌前驱病变的筛查效能。 结果 HR-HPV的检出率随着组织学病变级别的升高而增高。以宫颈活检结果为标准，HR-HPV检测筛查宫颈鳞状上皮内病变的灵敏度为94.2%，特异度为66.2%；TCT筛查的灵敏度为79.9%，特异度为86.8%；两种方法联合筛查的灵敏度为97.4%，特异度为58.2%。 结论 HR-HPV检测具有高灵敏度，更适合用于宫颈癌前病变的初筛。TCT特异性较高，适合作为HPV阳性人员的分流方法或与HR-HPV检测联合应用。
Abstract:
Objective To explore the application value of high-risk human papillomavirus (HR-HPV) detection and thinprep cytology test (TCT) in the screening of cervical precancerous lesions. Methods The screening data of cervical cancer in our hospital from January 2018 to December 2020 were retrospectively analyzed.A total of 15 162 cases who underwent TCT and HR-HPV combined screening were selected as the research objects, including 11 831 physical examinations and 3 331 gynecological patients, to understand the infection status of HR-HPV in different populations in Quanzhou, Fujian province.In addition, 1 220 cases of TCT, 1 428 cases of HR-HPV detection and 843 cases of combined screening data were selected, and the screening efficacy of different screening methods for cervical squamous cell carcinoma precursor lesions were compared with the results of cervical biopsy. Results The detection rate of HR-HPV increased with the increase of histological grade.Based on the results of cervical biopsy, the sensitivity and specificity of HR-HPV detection in screening cervical squamous intraepithelial lesions were 94.2% and 66.2%, respectively. The sensitivity and specificity of TCT screening were 79.9% and 86.8%, respectively.The sensitivity and specificity of the combined screening method were 97.4% and 58.2%, respectively.Conclusion HR-HPV detection is more suitable for the primary screening of cervical precancerous lesions due to its high sensitivity.TCT has high specificity and is suitable for using as a shunt method for HPV positive persons or in combination with HR-HPV detection.

参考文献/References:

[1] Berman T A，Schiller J T.Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases[J].Cancer，2017，123（12）：2219-2229.
[2] Chrysostomou A C，Stylianou D C，Constantinidou A，et al.Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing[J].Viruses，2018，10（12）：729-763.
[3] 王华庆，王岩，王朝华，等.子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识(简版)[J].中国病毒病杂志，2019，9（6）：401-418.
[4] Zhao X，Wu Q，Wang X，et al.The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women[J].Clin Microbiol Infect，2018，24（12）：1322-1327.
[5] Bhatla N，Singhal S.Primary HPV screening for cervical cancer[J].Best Pract Res Clin Obstet Gynaecol，2020，65：98-108.
[6] Maver P J，Poljak M.Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans[J].Clin Microbiol Infect，2020，26（5）：579-583.
[7] Tota J E，Bentley J，Blake J，et al.Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening[J].Prev Med，2017，98：15-20.
[8] 魏丽惠，赵昀，沈丹华，等.中国子宫颈癌筛查及异常管理相关问题专家共识(一)[J].中国妇产科临床杂志，2017，18（2）：190-192.
[9] 沈丹华.重视子宫颈癌筛查及诊治中病理医师的作用[J].中华妇产科杂志，2019，54（1）：3-6.
[10] Casey S，Harley I，Jamison J，et al.A rare case of HPV-negative cervical squamous cell carcinoma[J].Int J Gynecol Pathol，2015，34（2）：208-212.
[11] Tracht J M，Davis A D，Fasciano D N，et al.Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia [J].Cancer Cytopathol，2017，125（10）：795-805.
[12] Blatt A J，Kennedy R，Luff R D，et al.Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices[J].Cancer Cytopathol，2015，123（5）：282-288.
[13] Bergeron C，Giorgi-Rossi P，Cas F，et al.Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial[J].J Natl Cancer Inst，2015，107（2）：423-429.
[14] 赵雪莲，热米拉·热扎克，胡尚英，等.高危型HPV DNA单独检测及与薄层液基细胞学联合筛查对宫颈癌及宫颈高度病变的筛查效果比较[J].中华预防医学杂志，2018，52（5）：469-474.

相似文献/References:

[1]林联韵,高丽丹,吴莉春,等.永安市女性人乳头瘤病毒感染和基因亚型分布特点[J].福建医药杂志,2017,39(4):100.
[2]吴敏强.平潭地区男性高危人群人乳头瘤病毒基因亚型检测(附202例分析)[J].福建医药杂志,2017,39(5):73.
[3]黄 勉 林 珺 沈 张 金 琼 陶 红 吴三山 刘禹利.PAX1基因甲基化用于子宫颈癌临床应用价值探讨[J].福建医药杂志,2020,42(03):3.
　HUANG Mian,LIN Jun,SHEN Zhang,et al.Clinical application value of methylated PAX1 gene in cervical cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):3.

更新日期/Last Update: 2022-10-15